Edition:
United Kingdom

AnGes Inc (4563.T)

4563.T on Tokyo Stock Exchange

573JPY
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
¥573
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,459,697
52-wk High
¥884
52-wk Low
¥225

Chart for

About

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of... (more)
No analyst recommendations are available for .

Overall

Beta: 1.59
Market Cap(Mil.): ¥50,402.51
Shares Outstanding(Mil.): 78.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.23 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-AnGes submits CTN of hypertension DNA vaccine

* Says it submitted Clinical Trial Notification (CTN) of hypertension DNA vaccine to Therapeutic Goods Administration (TGA) in Australia

20 Jul 2017

BRIEF-Anges MG says exercise of options

* Says 20,000 units of its 29th series options were exercised to 2 million shares of its common stock from June 10 to June 12

12 Jun 2017

BRIEF-Anges expects to apply for approval to manufacture treatment for severe blockage of the arteries in the legs - nikkei

* Anges expects to apply in October for approval to manufacture and market treatment for severe blockage of the arteries in the legs - Nikkei Further company coverage:

09 Jun 2017

BRIEF- Anges MG announces exercise of options through private placement

* Says 12,500 units of its 29th series options were exercised to 1.3 million shares of its common stock from June 1 to June 9, through private placement

09 Jun 2017

BRIEF- Anges MG announces exercise of options

* Says 8,500 units of its 29th series options were exercised to 850,000 shares of its common stock from May 24 to May 31, through private placement

31 May 2017

Earnings vs. Estimates